Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Study: HBV infection reduces risk of liver metastasis in CRC patients

Colorectal cancer is the second leading cause of cancer-related deaths in Western countries. Metastatic liver disease more frequently develops metachronous metastasis following treatment of CRC.

9 Mar 2011

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the award of €2 million in funding over 30 months from the « Fond Unique Interministériel » (a French program supporting collaborative research projects) including an amount of €743,000 specifically allocated to BioAlliance Pharma.

5 Mar 2011

Wako i30 Immunoanalyzer incorporating Caliper's microfluidic LabChip technologies receives 510(k) clearance

Caliper Life Sciences, Inc. today announced that its licensee Wako Pure Chemical Industries, through its Wako Diagnostics division, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its uTASWako® i30 Immunoanalyzer and AFP-L3 and DCP Assays, which are used to assess liver cancer risk in patients with chronic liver disease.

4 Mar 2011

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Vertex Pharmaceuticals Incorporated announced today interim results from an ongoing, two-part, Phase 2 study evaluating telaprevir in combination with pegylated-interferon and ribavirin compared to pegylated-interferon and ribavirin alone in people who are infected with both genotype 1 hepatitis C virus and human immunodeficiency virus, also known as HCV-HIV co-infection.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

Turmeric may be 'the right spice' to fight colon cancer

Turmeric, a bright yellow spice from south Asia belonging to the ginger family, is the main ingredient in curries - and ancient wisdom suggests that it's also good for your health. Taking this wisdom to the laboratory, Tel Aviv University researchers have discovered that turmeric's active ingredient called curcumin amplifies the therapeutic activity of highly toxic anti-inflammatory drugs used to fight colon cancer when used at high doses.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

Wako Diagnostics, a division of Wako Chemicals USA, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the uTASWako i30 instrument with alpha-fetoprotein L3 (AFP-L3) and des-gamma-carboxy prothrombin (DCP) in vitro diagnostic (IVD) tests in the USA.

2 Mar 2011

Bristol-Myers Squibb awards $1 million grant to reduce hepatitis-related health disparities in Asia

The Bristol-Myers Squibb Foundation has awarded four new grants to help improve awareness, prevention and care of hepatitis B and hepatitis C in China and India.

25 Feb 2011

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

New research has determined that patients in the U.S. with hepatitis C virus are twice as likely to not have health insurance coverage compared with those without the disease.

24 Feb 2011

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

New research has determined that patients in the U.S. with hepatitis C virus (HCV) are twice as likely to not have health insurance coverage compared with those without the disease. In fact researchers found only a third of HCV infected Americans have access to antiviral therapy; the remaining are either uninsured or not candidates for therapy due to treatment contraindications. Details of this study are published in the March issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

24 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

New vaccine offers hope against Hepatitis C

Immunology: Three percent of the world's population is currently infected by hepatitis C. The virus hides in the liver and can cause cirrhosis and liver cancer, and it's the most frequent cause of liver transplants in Denmark.

24 Feb 2011

Cerasome filled molecular-sized bubbles to target liver cancer cells

Nanotechnology may open a new door on the treatment of liver cancer, according to a team of Penn State College of Medicine researchers. They used molecular-sized bubbles filled with chemotherapy drugs to prevent cell growth and initiate cell death in test tubes and mice.

23 Feb 2011

First robotically-assisted liver resection performed at Jefferson University Hospital

Cataldo Doria, M.D., Ph.D., Nicoletti Family Professor of Transplant Surgery at Jefferson Medical College of Thomas Jefferson University; director of the Division of Transplantation; and co-director of the liver tumor program at Thomas Jefferson University Hospital is the first surgeon at Jefferson to perform a robotically-assisted liver resection. He is only one of a handful of surgeons across the country certified to do so.

22 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

CPIC scientists find rates of liver cancer in US-born Hispanic men increased by 87%

Thirty-year-old Pedro Espinosa's chances of developing liver cancer just skyrocketed. Born in the United States and of Hispanic descent, Pedro falls into a category of men in California whose liver cancer rates have nearly doubled over the past two decades, according to a recent study.

16 Feb 2011

Two Uofl professors provide reference works in oncology field

Two University of Louisville School of Medicine professors recently authored reference works in the field of oncology, one focusing on the use of radiation treatment for childhood cancers and the other on hepatocellular carcinoma, or liver cancer.

14 Feb 2011

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital ("PUCH"), Beijing, China.

9 Feb 2011

LESSOnc technique promising new surgical option for certain liver cancers

Surgeons at UC San Diego Health System have identified a new application for "scarless" surgery tools that are normally used for natural orifice translumenal endoscopic surgery (NOTES).

9 Feb 2011

Liver Cancer News and Research

Further Reading

Study: HBV infection reduces risk of liver metastasis in CRC patients

BioAlliance Pharma awarded €2 million in funding to study Lauriad mucoadhesive technology

Wako i30 Immunoanalyzer incorporating Caliper's microfluidic LabChip technologies receives 510(k) clearance

Vertex announces positive interim results from telaprevir Phase 2 study in patients with HCV, HIV

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Turmeric may be 'the right spice' to fight colon cancer

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Wako receives FDA 510(k) clearance for uTASWako i30 with AFP-L3 and DCP assays

Bristol-Myers Squibb awards $1 million grant to reduce hepatitis-related health disparities in Asia

New research: Significant number of HCV patients in the U.S. does not have health insurance coverage

Lack of health insurance limits Hepatitis C patients' access to latest antiviral therapy

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

New vaccine offers hope against Hepatitis C

Cerasome filled molecular-sized bubbles to target liver cancer cells

First robotically-assisted liver resection performed at Jefferson University Hospital

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

CPIC scientists find rates of liver cancer in US-born Hispanic men increased by 87%

Two Uofl professors provide reference works in oncology field

Aushon BioSystems enters diagnostic development collaboration with Peking University Cancer Hospital

LESSOnc technique promising new surgical option for certain liver cancers

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News